Tuesday, August 20, 2013

Oh Irony

Good article.
A Dry Pipeline for Psychiatric Drugs
After a series of failed clinical trials in which novel antidepressants and antipsychotics did little or no better than placebos, the companies seem to have concluded that developing new psychiatric drugs is too risky and too expensive. This trend was obvious at the 2011 meeting of the American Society for Clinical Pharmacology and Therapeutics, where only 13 of 300 abstracts related to psychopharmacology and none related to novel drugs. Instead, they are spending most of their research dollars on illnesses like cancer, heart disease and diabetes, which have well-defined biological markers and are easier to study than mental disorders. 
Yes, well nothing in the pipeline seems like a great improvement over the output so far.
And I'm quite sure those diabetes researchers are closer to the answer anyway.

My hypothesis regarding Ketamine.